# A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC

> **NCT03491709** · PHASE1 · UNKNOWN · sponsor: **Dragonboat Biopharmaceutical Company Limited** · enrollment: 18 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** anti-EGFR monoclonal antibody
- **DRUG:** Cetuximab injection

## Key facts

- **NCT ID:** NCT03491709
- **Lead sponsor:** Dragonboat Biopharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-01
- **Primary completion:** 2019-09-17
- **Final completion:** 2019-12-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03491709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03491709, "A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03491709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*